Crossmark

First-in-human study assessing safety, tolerability, and pharmacokinetics of 2-hydroxybenzylamine acetate, a selective dicarbonyl electrophile scavenger, in healthy volunteers

Crossref DOI link: https://doi.org/10.1186/s40360-018-0281-7

Published Online: 2019-01-05

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pitchford, Lisa M. https://orcid.org/0000-0002-6402-0823
Rathmacher, John A.

Fuller, John C. Jr

Daniels, J. Scott

Morrison, Ryan D.

Akers, Wendall S.

Abumrad, Naji N.

Amarnath, Venkataraman

Currey, Patricia M.

Roberts, L. Jackson

Oates, John A.

Boutaud, Olivier
Funding

Funding for this research was provided by:

National Institute on Aging (AG055184)
License Information

Text and Data Mining valid from 2019-01-05

Version of Record valid from 2019-01-05
More Information

Article History

Received: 10 September 2018

Accepted: 20 December 2018

First Online: 5 January 2019

Ethics approval and consent to participate

: The study protocol was approved by the Vanderbilt University Institutional Review Board. All participants provided written informed consent before participating in the study.

: Not applicable.

: JCF, LMP, and JAR are employed by and NNA is co-founder and part owner of Metabolic Technologies, Inc., which has executed an agreement for the rights to license the intellectual property for 2-hydroxybenzylamine from Vanderbilt University. JSD and RDM are employed by Sano Informed Prescribing, which received payment for services provided for this study. WSA received payment for the clinical pharmacokinetic analysis.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below